Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer
Havrilesky LJ, Garfield CF, Barnett JC, Cohn DE

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1016/j.ygyno.2012.03.028

Original Paper URL

Indexing Status
Subject indexing assigned by NLM

MeSH
Antineoplastic Agents, Phytogenic /economics /supply & distribution; Antineoplastic Combined Chemotherapy Protocols /economics /therapeutic use; Carboplatin /administration & dosage /economics; Drug Costs /statistics & numerical data; Female; Humans; Markov Chains; Ovarian Neoplasms /drug therapy /economics; Paclitaxel /administration & dosage /economics /supply & distribution; Quality of Life; Taxoids /administration & dosage /adverse effects; United States

AccessionNumber
22012021499

Date bibliographic record published
04/12/2012